Berry Global to showcase inhalation solutions at DDL Conference; products include new lightweight PneumoHaler breath-actuated, multi-dose inhaler for asthma and COPD management and other drug delivery devices to improve patient experience and adherence

Sample article from our Consumer Wellness

November 27, 2023 (press release) –

Inhalation solutions that deliver a better patient experience, including improved adherence and administration, will be showcased by Berry Global at this year’s DDL Conference.

Leveraging the company’s sustainable design expertise and over 50 years of experience in the development of respiratory drug delivery devices, the new inhalation products help deliver a better healthcare experience by improving quality of care while helping to reduce costs and supporting the circular economy.

At the conference, Berry will show a range of models from its extensive portfolio of dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs) with or without dose indicators, breath-actuated inhalers, and digital inhalers.

A major highlight on the stand will be the company’s newly launched PneumoHaler, a lightweight, breath-actuated, multi-dose inhaler with a dose indicator for the effective management of asthma and chronic obstructive pulmonary disease (COPD). Designed to provide a ready-to-use solution for new inhalation treatments, the PneumoHaler eliminates the need for pharmaceutical companies to develop their own platforms, enabling the delivery of faster-to-market solutions. Equally important, the PneumoHaler helps enhance medication adherence caused by poor user technique of pMDIs.

Significant recent introductions in Berry’s DPI range include the RS01-X single-dose DPI with built-in sensors and digital services to track inhaler use and help improve adherence and technique, and the RS01 Size 2 capsule-based inhaler, which meets the increased demand for higher dose devices for the pulmonary delivery of systemic treatments and highly engineered, low-density powder formulations.

Berry will also demonstrate its market leadership in the CDMO of customized devices based on customers’ IP. Both standard and bespoke solutions can be developed and supplied from the company’s three facilities in Osnago (Italy), Mellrichstadt (Germany), and Bengaluru (Bangalore, India), providing a global reach and fast response.

“At Berry, we think Beyond Drug Delivery, and we help our customers Do Better, By Dosing better,” said Arturo Cubí, Business Development Director – Global Healthcare for Berry Global.

“This is our commitment to create patient-centric drug delivery inhalation solutions that enhance the user experience, improve disease management, and minimize environmental impact. We look forward to discussing customers’ specific requirements during DDL 2023.”

Learn more about the products and solutions offered in the global healthcare market.


* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order consumer wellness coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.